Nanobiotix is a late‑stage clinical biotechnology company developing physics‑based nanotherapeutics that amplify the effectiveness of radiotherapy. Its lead product, NBTXR3, is a radioenhancer that increases radiation absorption in solid‑tumor cells while sparing surrounding healthy tissue, and is being co‑developed and commercialized worldwide through a licensing partnership with Janssen Pharmaceutica. The technology aims to improve outcomes for patients with hard‑to‑treat cancers such as head, neck, and lung tumors.
Funding
$258.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EIHRFounders
Product
Problem
Radiotherapy for solid tumors often delivers insufficient dose to cancer cells while exposing surrounding healthy tissue to radiation, limiting treatment efficacy and increasing side effects. Additionally, many patients do not achieve durable responses, and metastatic disease remains a major cause of mortality.
Solution
Nanobiotix has created NBTXR3, a physics‑based nanoradioenhancer composed of hafnium oxide nanoparticles that are injected directly into the tumor. Once inside cancer cells, the particles amplify the energy deposited by external radiation, increasing the local dose without raising exposure to adjacent normal tissue. The enhanced tumor kill also stimulates an immune response that can target metastatic lesions. NBTXR3 is administered as a single intratumoral injection and is being co‑developed with Janssen Pharmaceutica for use in head‑and‑neck, lung and other solid cancers, aiming to improve response rates and overall patient outcomes.
Target Audience
Primary customers are oncology clinicians and hospital radiotherapy departments treating patients with solid tumors, particularly in head‑and‑neck and lung cancer, as well as pharmaceutical partners seeking to combine NBTXR3 with other therapies.
Features
- Hafnium oxide nanoparticle formulation designed for high atomic number to boost radiation dose locally
- Intratumoral injection enables precise delivery and rapid uptake by cancer cells
- Compatible with standard external‑beam radiotherapy equipment and protocols
- Single‑dose administration integrates into existing treatment schedules
- Induces immunogenic cell death, potentially enhancing systemic anti‑tumor immunity
- Scalable manufacturing process for clinical and commercial supply